Ventyx Biosciences, Inc. (VTYX) Tops Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazil’s Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Oil settles lower on peace hopes, Saudi attacks limit losses
- Britain will not join Canada-led defence bank initiative
Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress
May 9, 2024 4:01 PM EDTPhase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024Â in patients with early Parkinsons disease and in participants with obesity with certain additional cardiovascular risk factors
Cash, cash equivalents and marketable securities of $302.6 million as of March 31, 2024 are expected to fund planned operations into at least the second half of 2026
Ventyx to host conference call and webcast today at 4:30PM ET
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (Ventyx), a clinical-stage... More



